Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Bobylev (Smolensk, Russian Federation), S. Rachina (Moscow, Russian Federation), S. Avdeev (Moscow, Russian Federation), S. Rachin (Saint Petersburg, Russian Federation), D. Smirnova (Saint Petersburg, Russian Federation). C-reactive protein (C-RP) in patients with chronic heart failure (CHF) and community-acquired pneumonia (CAP): usefulness to guide antibiotic prescription. 2610

Member's Comments

No comment yet.

Related content which might interest you: C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 545s Year: 2005 Diagnosis on community-acquired pneumonia (CAP) in patients with congestive heart failure (CHF) Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Community-acquired pneumonia (CAP) and mortality risk in patients with congestive heart failure (CHF) Source: Eur Respir J 2002; 20: Suppl. 38, 443s Year: 2002 Procalcitonin (PCT) and C-reactive protein (CRP) as markers of the differential diagnosis of severe community acquired pneumonia (sCAP) Source: Annual Congress 2013 –Respiratory infections: a combination of problems needing early treatment Year: 2013 C-reactive protein (CRP) utility in severe community-acquired pneumonia (SCAP) prognosis Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Performance of rapid, bedside whole blood C-reactive protein (CRP) test as a diagnostic test for bacterial infection and pneumonia in patients with acute exacerbation of chronic obstructive pulmonary disease (AE COPD) Source: Eur Respir J 2007; 30: Suppl. 51, 557s Year: 2007 Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015 The discriminatory value of procalcitonin (PCT) and C-reactive protein (CRP) levels in HIV-seropositive patients presenting with community acquired pneumonia (CAP) due to pulmonary tuberculosis (PTB) compared with patients with pneumococcal pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 241s Year: 2004 C-reactive protein (CRP) as a marker of disease severity in community acquired pneumonia patients with sepsis Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012 Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia Source: Eur Respir J 2008; 32: 726-732 Year: 2008 Serum C-reactive protein (CRP) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Does the condition of chronic obstructive pumonary disease (COPD) have a prognostic benefit in patients with community-acquired pneumonia (CAP)? Source: Eur Respir J 2003; 22: Suppl. 45, 338s Year: 2003 Changes in levels of inflammatory markers (procalcitonin, C-reactive protein) in pregnant with community-acquired pneumonia (CAP) Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016 Antibacterial therapy of community-acquired pneumonia (CAP) at patients with cardiovascular diseases (CVD) Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP) Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia Year: 2007 Non-invasive ventilation (NIV) in community-acquired pneumonia CAP) and severe acute respiratory failure (ARF): Effectiveness and risk factors for failure and mortality Source: Annual Congress 2011 - Recent advances in noninvasive ventilation used for treating acute respiratory failure Year: 2011 Procalcitonin and C reactive protein as markers of treatment failure in community-acquired pneumonia Source: Annual Congress 2006 - Inflammation markers in community-acquired pneumonia Year: 2006 Surfactant protein D (SPD) and C-reactive protein (CRP) in patient with low respiratory tract infections (LRTI) Source: Annual Congress 2013 –Lung infections: a clinical point of view Year: 2013 Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients Source: Annual Congress 2011 - COPD management Year: 2011